Latest Regenerative Medicine News

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Osteopore Limited posted a 10% quarter-on-quarter revenue increase to AUD 754K in Q1 CY26, driven by new distribution deals across China, Latin America, and Hong Kong, alongside launching 3D printing services and securing innovative bone graft technologies in Asia Pacific.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

Osteopore Limited has drawn down an additional $250,000 on the second tranche of its redeemable convertible notes, continuing its strategic funding partnership with Advance Opportunities Fund. This incremental funding supports the company’s ongoing business and future growth initiatives.

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.